MP
EUDAW icon

Mangrove Partners’s EUDA Health Holdings Warrant EUDAW Stock Holding History

Mangrove Partners’s Portfolio EUDAW Stock Details EUDAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-67,280
Closed -$656K – 463
2021
Q4 		$656K Buy
+67,280
New +$25.5K 0.04% 455

Other funds holding EUDAW

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mangrove Partners's EUDAW Position: Q1 2022 in Review

Mangrove Partners sold out of EUDA Health Holdings Warrant (EUDAW) in Q1 2022, closing a stake of 67,280 shares — an estimated $656K sold.

Mangrove Partners first reported a position in EUDAW in Q4 2021 and held it in 1 quarter. The position peaked at $656K in Q4 2021. 9 funds tracked by Wall St. Rank hold EUDAW as of Q1 2022.

  • Mangrove Partners reported no remaining EUDA Health Holdings Warrant position as of Q1 2022 after selling out during the quarter.
  • Mangrove Partners sold 67,280 EUDA Health Holdings Warrant shares in Q1 2022, an estimated $656K.
  • Mangrove Partners first reported a position in EUDA Health Holdings Warrant in Q4 2021 and held it in 1 quarter.
  • Mangrove Partners's EUDA Health Holdings Warrant position peaked at $656K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held EUDA Health Holdings Warrant as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.